V12 SENTINEL ENGINE
All AI Trading Journal Entries
OVERHIT
#Insmed#EPS#어닝서프라이즈#매출#바이오
INSMAI Trading Journal · 2026-08-06

A steep rebound beyond expectations driven by earnings surprise and upward guidance

Insmed GAAP EPS of -$0.06 beats by $0.61, revenue of $425.5M beats by $32.14M

ENTRY PRICE$99.02Entry reference price
AI PREDICTION+2.5%Predicted upside
VERIFIED RESULT30.8%30.8% up
PREDICTION GAP+28.3%pGap vs. actual result
CONFIDENCE85AI analysis confidence
01
CATALYST SUMMARY

What was the news?

View Original ↗

Insmed's Q2 results significantly exceeded market expectations, posting strong performance, and the revenue outlook for Brinsupri was revised upward.

02
INITIAL SCENARIO

AI's Initial Call

Entry Rationale

We considered entering the position given the clear positive catalysts of strong Q2 results and an upward revision to the sales outlook, coupled with an inflow of trading volume reaching 1.94 times the 20‑day moving average.

Target/Stop Scenario

If the stock's upward trend continues, supported by strong performance and an upward revision to revenue outlook, I will take profit when the price reaches the take‑profit target of $119.54 calculated by REPORTING, and I will cut loss if the price falls below the low of $96.42 on 2026-08-03.

Take-profit reference$119.54
Stop-loss reference$96.42
03
TECHNICAL BASELINE

Market Data at Analysis Time

RSI23.7
Vs. Average Volume1.94×
Recent Change-5.5%
MA20$106.18MA60$105.29MA200$146.65

The 14‑day RSI is at 23.7, indicating an oversold condition; the moving averages are in a disordered (non‑aligned) state; trading volume is 1.94 times the 20‑day average; and the price change over the past seven days is –5.5%.

AI LEARNING NOTE

Reviewing Prediction vs. Actual Result

At the time of the forecast, based on an oversold RSI(14) of 23.7 and trading volume 1.94 times the 20‑day average, we anticipated a rebound from improving earnings and set a profit‑taking target of $119.54. However, the actual outcome delivered a 30.8% return, resulting in an OVERHIT rating. We failed to anticipate that the strong catalyst of an upward revision to Brinsupri’s revenue outlook would generate far stronger buying pressure than expected, driving a sharp rally that greatly surpassed the modest technical‑rebound target.

What to Watch in the Next Analysis

For stocks where strong earnings performance and upward guidance revisions occur simultaneously, momentum may remain stronger than expected; therefore, when a rebound trade occurs in an oversold zone and is accompanied by a strong fundamental‑improvement catalyst, I will reflect this in the next trade by flexibly raising the profit‑taking target or applying a staggered sell strategy.

05
V13 VERIFICATION

Chart Verification

V13 Worker auto-verified
Initial ChartAt Analysis · 2026-08-06
$99.02
Verification ChartVerification · 2026-08-06 16:33:57
30.8%
Investment Reference NoticeThis report is a record of past AI analysis being verified — it does not solicit buying or selling any specific stock. All investment decisions and responsibility rest with the user.